These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: P fimbria-specific B cell responses in patients with urinary tract infection.
    Author: Kantele A, Möttönen T, Ala-Kaila K, Arvilommi HS.
    Journal: J Infect Dis; 2003 Dec 15; 188(12):1885-91. PubMed ID: 14673769.
    Abstract:
    Local immune response may be important in defense against urinary tract infection (UTI). P fimbria, an important virulence factor of Escherichia coli, is a noteworthy candidate for use in a vaccine against pyelonephritis (PN). Eleven patients with PN and 14 patients with lower urinary tract infection (LUTI) caused by E. coli were studied for mucosa-derived antibody-secreting cells (ASCs) and for urinary antibodies. In the 10 patients with P-fimbriated (P+) E. coli, an ASC response to P fimbria was found in 5 of 5 patients who had PN and 1 of 5 patients who had LUTI. The response to P fimbria was stronger among patients with P+ PN than among patients with PN caused by non-P-fimbriated E. coli (P-) (P<.001) or patients with P+ LUTI (P<.001). The response to P fimbria was also stronger than the response to outer-membrane protein A among all patients with PN. P fimbria-specific urinary immunoglobulin A antibody levels were higher among patients with P+ PN than those with P- PN. The results show a P fimbria-specific local immune response, which further encourages the use of P fimbria in locally administrable UTI vaccines.
    [Abstract] [Full Text] [Related] [New Search]